Vitro Biopharma (VTRO) 10-K 28 Jan 25 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Oct. 31, 2024	Jan. 28, 2025	Apr. 30, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--10-31
Entity File Number	000-41766
Entity Registrant Name	VITRO BIOPHARMA, INC.
Entity Central Index Key	0000793171
Entity Tax Identification Number	84-1012042
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3200 Cherry Creek Drive South
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80209
City Area Code	(855)
Local Phone Number	848-7627
Title of 12(g) Security	Common Stock, par value $0.001 per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		4,460,535
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.001
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2024	Oct. 31, 2023
ASSETS
Cash	$ 571,360	$ 101,754
Accounts Receivable, Net	206,292	119,671
Inventory	115,365	170,752
Prepaid Expense	82,736	130,851
Deferred Offering Costs		2,656,326
Total Current Assets	975,753	3,179,354
Goodwill	3,171,581	3,608,949
Intangible Assets, Net	358,084	667,813
Property and Equipment, Net	139,552	320,414
Patents	89,548	82,325
Right of Use Asset – Operating Lease	346,091	476,241
Other Assets	8,438	8,438
Total Assets	5,089,047	8,343,534
LIABILITIES
Accounts Payable	2,163,920	2,288,697
Deferred Revenue, Net	525,387	525,387
Accrued Liabilities	1,806,419	1,310,240
2021 Series Convertible Notes Payable – Related Party	480,000	480,000
Accrued Interest Payable – Related Party	81,679	53,804
2024 Senior Secured Convertible Notes Payable – Stock Settled	4,718,750
Derivative/Warrant Liability	154,966
Current Maturities of Capital Lease Obligations	12,081	61,832
Current Maturities of Operating Lease Obligations	119,486	130,150
Total Current Liabilities	10,062,688	4,850,110
Capital Lease Obligations, Net of Current Portion	5,042	17,123
Operating Lease Obligation, Net of Current Portion	226,605	346,091
Unsecured 6% Note Payable – Related Party	767,288	767,288
Unsecured 4% Note Payable – Related Party	1,221,958	1,221,958
2022 Series Convertible Notes Payable	200,000	200,000
2023 Series Convertible Notes Payable - Stock Settled, Net	353,114	340,715
2023 Series B Convertible Notes Payable – Stock Settled, Net	507,273	421,018
Derivative/Warrant Liability	126,006	893,263
Long Term Accrued Interest Payable	240,123	92,311
Long Term Accrued Interest Payable – Related Party	379,923	284,747
Total Long-Term Liabilities	4,027,332	4,584,514
Total Liabilities	14,090,020	9,434,624
STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred Stock, 5,000,000 Shares Authorized, par value $0.001; Series A Convertible Preferred Stock, 250,000 Shares Authorized, 0 and 0 Outstanding, respectively
Common stock, 19,230,770 Shares Authorized, par value $0.001, 4,460,535 and 4,430,535 Outstanding, respectively	4,460	4,430
Additional Paid in Capital	29,028,260	27,064,613
Less Treasury Stock	(84,000)	(84,000)
Accumulated Deficit	(37,949,693)	(28,076,133)
Total Stockholders’ (Deficit) Equity	(9,000,973)	(1,091,090)
Total Liabilities and Stockholders’ (Deficit) Equity	$ 5,089,047	$ 8,343,534

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2024	Oct. 31, 2023	Jun. 23, 2023
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	19,230,770	19,230,770
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares outstanding	4,460,535	4,430,535
Series A Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Total Revenue	$ 1,855,644	$ 1,763,451
Less Cost of Goods Sold	(426,189)	(298,051)
Gross Profit	1,429,455	1,465,400
Operating Costs and Expenses:
Selling, General and Administrative	6,623,878	6,062,758
Research and Development	618,270	206,406
Write-off of Offering Costs	2,656,962
Impairment Expense	683,394	577,852
Loss From Operations	(9,153,049)	(5,381,616)
Other Expense:
Interest Expense	(4,242,595)	(270,182)
Other Project Income, Net		191,746
Gain on Extinguishment of Debt	740,724
Unrealized Gain on Derivative/Warrant Liability	2,781,360	103,335
Net Loss Available to Common Stockholders	$ (9,873,560)	$ (5,356,717)
Net Loss per Common Share, Basic	$ (2.21)	$ (1.21)
Net Loss per Common Share, Diluted	$ (2.21)	$ (1.21)
Shares Used in Computing Net Loss per Common Share, Basic	4,459,224	4,430,535
Shares Used in Computing Net Loss per Common Share, Diluted	4,459,224	4,430,535
Product [Member]
Total Revenue	$ 1,821,894	$ 1,702,451
Product Sales Related Parties [Member]
Total Revenue	33,750	36,000
Consulting Revenue [Member]
Total Revenue		$ 25,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Oct. 31, 2022		$ 4,430	$ 25,634,826	$ (84,000)	$ (22,719,416)	$ 2,835,840
Balance, shares at Oct. 31, 2022		4,430,535
Stock based compensation			1,292,270			1,292,270
Forgiven Accrued Payables – Related Party			137,953			137,953
Payment for fractional warrants - recapitalization			(436)			(436)
Net Loss					(5,356,717)	(5,356,717)
Balance at Oct. 31, 2023		$ 4,430	27,064,613	(84,000)	(28,076,133)	(1,091,090)
Balance, shares at Oct. 31, 2023		4,430,535
Stock based compensation			1,513,677			1,513,677
Net Loss					(9,873,560)	(9,873,560)
Stock Issued for Services		$ 30	449,970			450,000
Stock Issued for Services, shares		30,000
Balance at Oct. 31, 2024		$ 4,460	$ 29,028,260	$ (84,000)	$ (37,949,693)	$ (9,000,973)
Balance, shares at Oct. 31, 2024		4,460,535

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Operating Activities
Net Loss	$ (9,873,560)	$ (5,356,717)
Adjustment to Reconcile Net Loss:
Other Project Income, Net		(191,746)
Gain on Extinguishment of Debt	(740,724)
Unrealized Gain on Derivative/Warrant Liability	(2,781,360)	(103,335)
Depreciation Expense	180,862	153,023
Amortization Expense	63,702	131,736
Impairment Expense	683,394	577,852
Amortization of Operating Lease – ROU Asset	130,150	72,536
Accretion of Debt Discount	3,952,197	40,730
Stock Based Compensation	1,513,677	1,292,270
Common Stock Issued for Services	450,000
Write-off of Offering Costs	2,656,962
Changes in Assets and Liabilities
Accounts Receivable	(86,621)	(46,134)
Inventory	55,387	109,386
Prepaid Expenses	48,115	9,908
Prepaid Project Costs		159,493
Accounts Payable	(125,413)	640,325
Deferred Revenue, Net		125,387
Operating Lease Obligation	(130,150)	(72,536)
Accrued Liabilities	496,180	370,718
Accrued Liabilities – Related Party		(94,995)
Accrued Interest	147,812	89,106
Accrued Interest – Related Parties	123,051	118,736
Other Assets		5,422
Net Cash Used in Operating Activities	(3,236,339)	(1,968,835)
Investing Activities
Acquisition of Property and Equipment		(121,497)
Patent Costs	(7,223)	(73,935)
Net Cash Used in Investing Activities	(7,223)	(195,432)
Financing Activities
Deferred Offering Costs		(130,138)
Issuance of 2024 Senior Secured Convertible Notes Payable	3,775,000
Issuance of 2023 Series Convertible Notes Payable - Stock Settled		405,000
Issuance of 2023 Series B Convertible Notes Payable – Stock Settled		1,312,600
Capital Lease Principal Payments	(61,832)	(62,979)
Net Cash Provided by Financing Activities	3,713,168	1,524,483
Total Cash Provided (Used) During the Period	469,606	(639,784)
Beginning Cash Balance	101,754	741,538
Ending Cash Balance	571,360	101,754
Cash Paid for Interest	19,533	21,610
Cash Paid for Income Taxes
Supplemental Schedule of Non-Cash Financing Activities:
Premium on issuance of 2024 Senior Secured Convertible Notes	2,895,835
Derivative/Warrant Liability on 2024 Senior Secured Convertible Notes	3,159,788
Discount on Derivative/Warrant Liability on 2024 Senior Secured Convertible Notes	6,055,624
Premium on issuance of 2023 Series and 2023 B Series Notes Payable - Stock Settled		572,533
Derivative/Warrant Liability on 2023 Series and 2023 B Series Notes Payable		996,597
Discount on Derivative/Warrant Liability on 2023 Series and 2023 B Series Notes Payable		1,569,131
Forgiveness of Accrued Liabilities – Related Party		137,953
Deferred Offering Costs Recorded as Accounts Payable		1,043,766
Right of Use Asset and Operating Lease Obligation Recognized under ASC Topic 842		$ 271,396

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Oct. 31, 2024
Insider Trading Arrangements
No insider trading flag	true

NATURE OF ORGANIZATION AND SUMM

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Organization and Description of Business Vitro Biopharma, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on March 31, 1986, under the name Imperial Management, Inc. On December 17, 1986, the Company merged with Labtek, Inc., a Colorado corporation, with the Company being the surviving entity and the name of the Company was changed to Labtek, Inc. The name was then changed to Vitro Diagnostics, Inc. on February 6, 1987. From November of 1990 through July 31, 2000, the Company was engaged in the development, manufacturing, and distribution of purified human antigens (“Diagnostics”) and related technologies. The Company also developed cell technology including immortalization of certain cells, which allowed entry into other markets besides Diagnostics. In August 2000, the Company sold the Diagnostics business, following which it focused on developing therapeutic products, its stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. On February 3, 2021, the Company filed an amendment to the articles of incorporation with the Nevada Secretary of State, changing the name of the Company to Vitro BioPharma, Inc. Summary of Significant Accounting Policies Basis of Presentation On June 23, 2023, the Board of Directors of the Company approved a 1-for-26 reverse stock split 0.001 The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Basis of Consolidation The consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, Fitore, Inc. (“Fitore”) and InfiniVive MD, LLC (“InfiniVive”). Cash Equivalents For the purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Concentrations During the years ended October 31, 2024 and 2023, 2 % and 2 % respectively, of the Company’s total revenues were derived from sales to an entity controlled by the Company’s former Chief Executive Officer and President, Dr. Jack Zamora (“Dr. Zamora”) (Note 10). Dr. Zamora is also a 30 % stockholder. During the year ended October 31, 2024, 33 % and 31 % of the Company’s total revenue was attributable to product sales to two customers. Also, during the year ended October 31, 2023, two customers accounted for 43 % and 15 % of the Company’s revenues. Other than the revenues derived through sales the customers referenced herein, no customer accounted for greater than 10 % of the Company’s gross sales for the years ended October 31, 2024 or 2023. In addition to the product revenue concentrations noted above, the Company recognized $ 25,000 in consulting revenue from a single client during the year ended October 31, 2023. This amount was 1 % of the total revenue recognized for the period. Deferred Offering Costs The Company defers, as Current Assets, the direct incremental costs of raising capital through equity offerings, until such time as the offering is completed or abandoned. At the time of the offering completion, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. During the years ended October 31, 2024 and 2023 the Company recorded as expense $ 2,656,962 0 Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements. For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time. Control is considered transferred over time if any one of the following criteria is met: ● The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs; ● The entity’s performance creates or enhances an asset; or ● The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date. For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue. The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below: Sale of research and development product Sales of research and development product include the sale of stem cell medium Sale of therapeutic product: Includes cell culture media to be used in therapeutic treatment. Shipping: Includes amounts charged to customers for shipping products. Consulting Revenue: The Company has agreed to assist another party to develop an FDA-approved biological product. Revenues are recognized when certain contractual milestones are achieved. Fitore product sales online: Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. InfiniVive product sales: InfiniVive, via call-in orders, sells exosomes and daily cosmetic serum Disaggregation of revenue The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Year Ended Year Ended Revenues: Research and development products $ 426,846 $ 574,293 AlloRx Stem Cells to Foreign Third-Party Clinics 1,285,117 893,474 Consulting revenue - 25,000 InfiniVive products 128,940 204,414 Fitore products 14,741 66,270 Total $ 1,855,644 $ 1,763,451 Total Revenues $ 1,855,644 $ 1,763,451 Deferred Revenue The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) executed between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been to be renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement. The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of October 31, 2023, the Company has net deferred $ 525,387 685,005 159,618 The table below summarizes Deferred Revenues as of October 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, 2023 Other Project Income Recognized Net Revenue Deferred October 31, 2024 Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of October 31, 2023: October 31, 2022 Other Project Income Recognized Net October 31, 2023 Deferred Revenue $ 650,000 $ (191,746 ) $ 67,133 $ 525,387 Total $ 650,000 $ (191,746 ) $ 67,133 $ 525,387 As of July 31, 2023, upon the expiration of the European Wellness Agreement, the Company recognized $ 250,000 58,254 Accounts Receivable Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the allowance method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of October 31, 2024 and 2023, total accounts receivable amounted to $ 206,292 119,671 975 975 As of October 31, 2024, three customers accounted for 55 20 10 39 35 10 Basic Loss Per Share The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the years ended October 31, 2024 and 2023, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE October 31, 2024 October 31, 2023 Stock options outstanding 1,112,923 1,112,923 Shares to be issued in connection with exercise of warrants 261,650 444,454 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settlement 30,915 13,102 2023 Series Convertible Notes Payable – Stock Settled - warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable - Stock Settled 98,051 41,487 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured Convertible Notes Payable – Stock Settled 857,955 - 2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable 289,583 - 2024 Pre-funded Warrants 1,107,500 - Total 3,827,688 1,681,077 Anti-dilutive shares 3,827,688 1,681,077 Inventory Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES October 31, 2024 October 31, 2023 Raw materials $ - $ 18,856 Finished goods 115,365 151,896 Total inventory $ 115,365 $ 170,752 The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the years ended October 31, 2024 and 2023, the Company did not record any impairment expense. Patents Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of October 31, 2024 and 2023 were $ 89,548 82,325 Leases In May 2023, the Company executed a new office lease for its executive offices, with the lease starting July 1, 2023. The Company recognized an initial operating lease right-of-use asset of $ 271,396 271,396 130,150 72,536 Property and Equipment Property, equipment, and leasehold improvements are recorded at historical cost. The cost of property and equipment is depreciated over the estimated useful lives, when placed in service (ranging from 3 5 Intangible Assets and Impairment Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. The Company periodically reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less that the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Goodwill Goodwill is the excess of acquisition cost over the fair value of the net assets of acquired businesses. The Company does not amortize goodwill but assesses goodwill for impairment at least annually or when there has been a material change in circumstances, using the market approach. Stock Based Compensation The Company accounts for expenses associated with shares issued for services using the fair value method following the guidance outlined in Section 718-10 of the FASB ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions). That cost is recognized over the period during which the service is provided. No compensation cost is recognized for equity instruments for which service is not provided or rendered. Recent Accounting Standards On August 5, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. This ASU is effective for fiscal years beginning after December 31, 2023. The Company is evaluating the impact the adoption will have on the financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company has incurred net losses of approximately $ 9.9 9.1 These factors raise substantial doubt about the Company’s ability to continue as a going concern. In view of these matters, realization of certain of the assets in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and generate additional revenues and profit from operations. Management plans to address the going concern include but are not limited to raising additional capital through an attempted public and/or private offering of equity securities, as well potentially issuing additional debt instruments. The Company also has various initiatives underway to increase revenue generation through diversified offerings of products and services related to its stem cell technology and analytical capabilities. The goal of these initiatives is to achieve profitable operations as quickly as possible. Various strategic alliances that are ongoing and under development are also critical aspects of management’s overall growth and development strategy. There is no assurance that these initiatives will yield sufficient capital to maintain the Company’s operations. There is no assurance that the ongoing capital raising efforts will be successful. Should management fail to successfully raise additional capital and/or fully implement its strategic initiatives, it may be compelled to curtail part or all of its ongoing operations. The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has historically financed its operations primarily through various private placements of debt and equity securities.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Oct. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 3 – FAIR VALUE MEASUREMENT ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a hierarchy for inputs used in measuring fair value for financial assets and liabilities that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows: ● Level 1: Quoted prices available in active markets for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; and ● Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash or valuation models. The financial assets and liabilities are classified in the Consolidated Balance Sheets based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. As disclosed in Note 7, the two tranches of 2023 Series Convertible Notes Payable - Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. Similarly, the tranche of 2024 Series Senior Secured convertible notes – Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. The derivative liabilities described below only relate to (i) the warrants included with the two tranches of the 2023 Series Convertible Notes Payable – Stock Settled debt and (ii) the warrants included with 2024 Series Senior Secured convertible note – Stock Settled debt. The estimated fair values as of the issuance date of these three tranches of notes are presented in Note 7. As of October 31, 2024 and 2023, the estimated fair values of the Company’s financial liabilities are presented in the following table: SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES October 31, 2024 2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability $ 9,024 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 116,982 2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 154,966 Total $ 280,972 October 31, 2023 2023 Series Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability $ 63,969 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 829,294 Total $ 893,263 The following table presents a roll-forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2024 Series Senior Secured Convertible Notes Payable and its 2023 Series Convertible Notes Payable, categorized as Level 3: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS Year Ended Year Ended October 31, 2023 Beginning Balance $ 893,263 $ - Additions 3,159,788 996,598 Subtractions (990,719 ) - Total (gains) or losses (realized/unrealized) (2,781,360 ) (103,335 ) Ending Balance $ 280,972 $ 893,263 During the years ended October 31, 2024 and 2023, the unrealized gain on the Derivative Warrant Liability associated with the two tranches of 2023 Series Convertible Notes Payable – Stock Settled was $ 767,257 103,335 During the year ended October 31, 2024, the unrealized gain on the Derivative Warrant Liability associated with the 2024 Series Senior Secured convertible notes payable – stock settled was $ 2,014,103 The fair value of the warrants granted in connection with the two tranches of 2023 Series Convertible Notes Payable-Stock Settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED October 31, 2024 October 31, 2023 Risk-free interest rate - % 3.60 3.93 % Dividend yield - % 0.00 % Volatility factor - % 161.52 200.29 % Weighted average expected life (years) - 2.5 The fair value of the warrants granted in connection with the 2024 Series Senior Secured convertible notes payable - stock settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED October 31, 2024 October 31, 2023 Risk-free interest rate 3.99 4.61 % - % Dividend yield 0.00 % - % Volatility factor 131.93 135.58 % - % Weighted average expected life (years) 2.5 - Estimated Fair Value of Financial Assets and Liabilities Not Measured at Fair Value The Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable, and Convertible Notes Payable. The carrying values of cash, accounts receivable and accounts payable are representative of their fair values due to their short-term maturities. The carrying amount of the Company’s Convertible Notes Payable approximates fair value as they bear interest over the term of the loans.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Oct. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates: SCHEDULE OF PROPERTY AND EQUIPMENT October 31, 2024 October 31, 2023 Leasehold improvements $ 12,840 $ 12,840 Property and equipment 1,046,925 1,046,925 Total cost 1,059,765 1,059,765 Less accumulated depreciation (920,213 ) (739,351 ) Net property and equipment $ 139,552 $ 320,414 Depreciation expense for the years ended October 31, 2024 and 2023 was $ 180,862 153,023

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Oct. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2024: SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL Remaining Cost Accumulated Amortization and Impairment Net Carrying Trademarks and tradenames 11.75 $ 693,330 $ (534,654 ) $ 158,676 Patents, know-how and unpatented technology 11.75 710,060 (510,652 ) 199,408 Customer relationships 0 114,536 (114,536 ) - Total 1,517,926 (1,159,842 ) 358,084 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (1,351,459 ) $ 3,171,581 The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2023: Remaining Cost Accumulated Amortization and Impairment Net Carrying Trademarks and tradenames 12.75 $ 693,330 $ (391,214 ) $ 302,116 Patents, know-how and unpatented technology 12.75 710,060 (356,648 ) 353,412 Customer relationships 0.75 114,536 (102,251 ) 12,285 Total 1,517,926 (850,113 ) 667,813 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (914,091 ) $ 3,608,949 The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31; SCHEDULE OF FUTURE AMORTIZATION EXPENSE 2025 $ 30,475 2026 30,475 2027 30,475 2028 30,475 2029 30,475 Total $ 152,375 During the years ended October 31, 2024 and 2023, the Company recorded amortization expense of $ 63,702 131,736 49,431 243,795 196,595 334,057 437,368

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Oct. 31, 2024
Lease Obligations
LEASE OBLIGATIONS	NOTE 6 – LEASE OBLIGATIONS The Company accounts for its leases in accordance with ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). The Company’s operating lease consists of a lease for office space. The Company’s finance lease activities consist of leases for equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The office lease contains an option to a renewal period of five years In May 2023, the Company executed a new office lease for 2,978 271,396 271,396 130,150 72,536 The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets: SCHEDULE OF BALANCE SHEET RELATED TO LEASES Leases Balance Sheet Location October 31, 2024 October 31, 2023 Assets Noncurrent: Operating Right-of-use asset – operating lease $ 346,091 $ 476,241 Finance Property and equipment, net 3,351 33,294 Total Lease Assets $ 349,442 $ 509,535 Liabilities Current: Operating Operating lease liabilities $ 119,486 $ 130,150 Finance Finance lease liabilities 12,081 61,832 Noncurrent: Operating Operating lease liabilities 226,605 346,091 Finance Finance lease liabilities 5,042 17,123 Total Lease Liabilities $ 363,214 $ 555,196 The following table shows the classification and location and the Company’s lease costs in the Consolidated Statements of Operations: SCHEDULE OF OPERATIONS RELATED TO LEASES Location 2024 2023 Statements of Operations Years Ended October 31, Location 2024 2023 Operating lease expense General and administrative expense $ 203,557 $ 203,274 Finance lease expense: Interest on lease liability Interest expense 7,992 9,795 Total Lease expense $ 211,549 $ 213,069 Minimum contractual obligations for the Company’s leases (undiscounted) as of October 31, 2024 were as follows: SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES Operating Finance Fiscal year 2025 $ 163,902 $ 12,803 Fiscal year 2026 166,760 5,150 Fiscal year 2027 84,609 - Fiscal year 2028 67,734 - Fiscal year 2029 67,734 - Thereafter 45,156 - Total Lease Payments $ 595,895 $ 17,953 Less Imputed interest (249,804 ) (830 ) Total lease liability $ 346,091 $ 17,123 The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated: SCHEDULE OF OTHER INFORMATION RELATED TO LEASES October 31, 2024 October 31, 2023 Operating Leases Finance Leases Operating Leases Finance Leases Weighted-average remaining lease term (in years) 4.0 1.34 4.9 1.41 Weighted-average discount rate (1) 10.00 % 6.67 % 10.00 % 7.49 % (1) The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases. The following table includes other quantitative information for the Company’s leases for the periods indicated: SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES 2024 2022 Years Ended October 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities Cash payments for operating leases $ 180,581 $ 133,598 Cash payments for finance leases $ 65,387 $ 71,566 The Company recorded amortization of the operating lease right-of-use asset of $ 130,150 72,536

DEBT

DEBT	12 Months Ended
	Oct. 31, 2024
Debt Disclosure [Abstract]
DEBT	NOTE 7 – DEBT The table below presents outstanding debt instruments as of October 31, 2024 and October 31, 2023: SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS October 31, 2024 October 31, 2023 Short Term 2021 Series convertible notes – related party $ 480,000 $ 480,000 2024 Senior secured convertible notes payable 4,718,750 - Total Short-Term Debt 5,198,750 480,000 Long Term Unsecured 6% note payable – related party $ 767,288 $ 767,288 Unsecured 4% note payable – related party 1,221,958 1,221,958 2022 Series convertible notes 200,000 200,000 2023 Series convertible notes – stock settled 405,000 405,000 Discount 2023 Series convertible notes (51,886 ) (64,285 ) 2023 Series B convertible notes – stock settled 1,312,600 1,312,600 Discount 2023 Series B convertible notes (805,327 ) (891,582 ) Total Long-Term Debt 3,049,633 2,950,979 Total Debt $ 8,248,383 $ 3,430,979 The table below presents the future maturities of outstanding debt obligations as of October 31, 2024: SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS Fiscal year 2025 $ 5,198,750 Fiscal year 2026 1,989,246 Fiscal year 2027 200,000 Fiscal year 2028 1,717,600 Total $ 9,105,596 Unsecured 6% Note Payable - Related Party Interest expense on this note was $ 46,163 46,037 184,275 138,112 Unsecured 4% Note Payable - Related Party Interest expense on this note was $ 49,012 48,879 195,648 146,635 2021 Series Convertible Notes - Related Party The remaining principal balance outstanding on the 2021 Series Convertible notes amounted to $ 480,000 480,000 July 31, 2024 27,875 23,821 81,679 53,804 225,000 25,000 50,000 2022 Series Convertible Notes During June and July, 2022, the Company issued a total of $ 200,000 5 5,000,000 10,028 10,000 23,233 13,205 2023 Series Convertible Notes – Stock Settled On January 6, 2023, the Company sold $ 405,000 8 On various dates during March and April 2023, the Company sold $ 787,600 8 On various dates during June and July 2023, the Company sold $ 525,000 8 The sale and purchase were made through a Convertible Note and Warrant Purchase Agreement (“Purchase Agreement”) entered into with each investor. The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt and ASC 815 “Derivatives and Hedging” to account for the derivative related to the notes and also to determine the number of warrants to be issued at the time of the issuance of the January 2023 Notes, March 2023 Notes, or the June 2023 Notes. Each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes bear interest at the rate of eight per cent per annum and are payable solely in shares of the Company’s common stock. Each of the January 2023 Notes, March 2023 Notes, and June 2023 Notes may be converted at any time at the option of the holder and are payable in full at the earliest of (i) the completion of a “Qualified Financing,” as defined below, (ii) a change in control, (iii) in the event of default, or (iv) the maturity date, which is five years from the date of issuance. A Qualified Financing is defined in the Purchase Agreement as any financing completed after the date of issuance of either the January 2023 Notes, March 2023 Notes, or June 2023 Notes involving the sale of the Company’s equity securities primarily for capital raising purposes resulting in gross proceeds to the Company of at least $ 5 The Discounted Qualified Financing Price is defined as the per share price at which the shares of the Qualified Financing Securities are sold in such Qualified Financing as determined for accounting purposes under GAAP, multiplied by 0.75 200,000,000 Each January 2023 Warrant issuable by the Company pursuant to the Purchase Agreement entitles the holder to purchase that number of fully paid and nonassessable shares of the Company’s common stock determined (A) in the case following a Qualified Financing, by dividing (i) the sum of the aggregate outstanding principal amount of the January 2023 Note plus all accrued and unpaid interest thereon at the time of conversion multiplied by 0.25 0.75 16.25 1 to 26 reverse stock split Each March 2023 Warrant and June 2023 Warrant issuable by the Company pursuant to the Purchase Agreement entitles the holder to purchase that number of fully paid and nonassessable shares of the Company’s common stock determined (A) in the case following a Qualified Financing, by dividing (i) the sum of the aggregate outstanding principal amount of the March 2023 Note plus all accrued and unpaid interest thereon at the time of conversion by (ii) the quotient of the Discounted Qualified Financing Price divided by 0.75 16.25 five years Participation Rights 200 The Company contemplated ASC 480-10-30-7 related to the valuation of the embedded conversion feature contained in the January 2023 Notes, March 2023 Notes, and June 2023 Notes. The Company deemed that the most likely scenario to be utilized for valuing the conversion feature was a qualified financing. Therefore, the Company deemed that the January 2023 Notes, March 2023 Notes, and June 2023 were issued at a premium related to the definition of Discounted Qualified Financing Price contained in the Purchase Agreement. The premium recognized at the inception of January 2023 Notes was $ 135,000 262,533 175,000 The Company assessed the January 2023 Warrants, March 2023 Warrants, and June 2023 first under ASC 480. Based on the attributes of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. At issuance, the Company recorded a warrant liability related to the January 2023 Warrants of $ 73,213 135,000 73,213 208,213 568,574 262,533 568,574 831,108 354,810 175,000 354,180 529,810 The combination of the $ 135,000 208,213 73,213 13.0 13.0 12,400 8,927 54,946 9,243 The combination of the $ 262,533 831,108 568,574 44.6 44.6 52,724 22,176 427,408 70,973 The combination of the $ 175,000 529,810 354,810 39.5 39.5 33,532 9,627 284,903 23,119 During the years ended October 31, 2024 and 2023 the Company recorded $ 32,489 26,240 63,181 37,314 42,115 15,551 58,729 26,240 100,495 37,314 57,666 15,551 2024 Series Senior Secured Convertible Notes – Stock Settled On November 16, 2023 and January 10, 2024, the Company entered into securities purchase agreements (the “January Purchase Agreements”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “January Series 2024 Notes”) in the principal amount of $ 2,500,000 1,250,000 2,000,000 1,000,000 20 On April 11, 2024, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “April Series 2024 Notes”) in the principal amount of $ 218,750 175,000 20 On May 13, 2024, the Company entered into securities purchase agreements (the “May Purchase Agreement”) with accredited investors, pursuant to which the Company issued and sold to the investors, in a private placement, (i) senior secured convertible notes (the “May Series 2024 Notes”) in the principal amount of $ 375,000 300,000 20 On June 21, 2024, the Company entered into a letter agreement (the “Target Extension Agreement”) with Target Capital 16 LLC (“Target”). Pursuant to the Target Extension Agreement, the maturity date of the January Series 2024 Notes of the Company held by Target, in the aggregate original principal amount of $ 3,750,000 On July 16, 2024, the Company entered into a second letter agreement (the “Target Consolidation Agreement”) with Target. Pursuant to the Target Consolidation Agreement, in consideration of an additional $ 300,000 3,300,000 825,000 4,125,000 The January Series 2024 Notes, April Series 2024 Notes, May Series 2024 Notes, and July Series 2024 Notes are collectively the “Series 2024 Notes.” The January Series 2024 Warrants, April Series 2024 Warrants, and May Series 2024 Warrants are collectively the “Series 2024 Warrants.” No Series 2024 Warrants were issued with the July Series 2024 Notes. Interest on the Series 2024 Notes will accrue commencing on the earlier of the maturity date or upon an event of default, at the annual rate of 20%, due the first day of each calendar month following such date. The January Series 2024 Notes will mature at the earlier of (i) six months from the issuance date (the “Original Maturity Date”) and (ii) the occurrence of a Liquidity Event (as defined in the January Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “January Extension Period”). The April Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the April Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “April Extension Period”). The May Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the May Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “May Extension Period”). The July Series 2024 Notes will mature on October 16, 2024 (the “Original Final Maturity Date”), provided that, if the Company (A) will have been diligently pursuing the consummation of a Liquidity Event (as defined in the Notes) through such date (as evidenced by the filing of a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended) and (y) will have delivered an extension notice, then the Original Final Maturity Date will be extended to November 16, 2024 (the “Extended Final Maturity Date”), and (B) will have consummated a Liquidity Event on or before the Original Final Maturity Date or Extended Final Maturity Date, then the Extended Final Maturity Date will be extended by 180 days from the date of such consummation. The Series 2024 Notes are secured by all of the Company’s assets pursuant to a security agreement between the Company and the investors. The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale. The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt, ASC 470 “Debt,” and ASC 815 “Derivatives and Hedging” to account for Series 2024 Notes and Series 2024 Warrants. The Company contemplated ASC 480-10-30-7 related to the valuation of the embedded conversion feature contained in the Series 2024 Notes and determined that the value delivered to the investor is identical in all scenarios and only the number of shares differ. The number of shares are issued at a premium as there is a discount applicable in the case of a Liquidity Event. In order to determine the conversion price of the Series 2024 Notes, the Company analyzed the guidance in ASC 470 related to multi-step discounts. The Company deemed that the most likely scenario to be utilized for valuing the conversion feature was a conversion following a Liquidity Event at the option of the investor during the Extension Period as this represents the most advantageous scenario from the perspective of the investor with the shortest period in which the investor could recognize a return on its investment. Because the Company filed an amendment to its Form S-1 Registration Statement on February 2, 2024 which contemplates that, following effectiveness, the selling shareholders may offer their shares at a fixed price of $ 15.00 15.00 416,667 2,500,005 24,306 145,840 41,666 249,990 5.00 6.00 5.50 5.50 1,250,000 249,995 The Company assessed the Series 2024 Warrants first under ASC 480. Based on the attributes of the Series 2024 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the Series 2024 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. Because the scenario under which the Series 2024 Notes are analyzed assumes a Liquidity Event, the scenarios under which to analyze the Series 2024 Warrants should also contain a Liquidity Event. As such, the assumed exercise price is $ 15.00 250,000 14,583 25,000 2,732,304 157,733 269,752 2,500,005 750,000 2,732,304 5,232,309 145,840 43,750 157,733 303,573 249,990 75,000 269,752 519,742 The combination of the $ 2,500,005 750,000 5,232,309 3,482,304 659 624 3,482,304 0 Pursuant to ASC 480, the Company assessed the January Series 2024 Notes and the July Series 2024 Notes comparing the present value of the cash flows of both notes at the January Series 2024 Notes effective interest rate. Because the difference between the present value of the January Series 2024 Notes and July Series 2024 Notes cash flows was greater than 10%, the two sets of notes were deemed to be substantially different and, as such, the extinguishment of January Series 2024 Notes were recorded as a gain in the statement of operations. Immediately prior to the extinguishment, the Company recorded a gain on the fair value of the warrant liability of $ 1,713,320 300,000 75,000 990,719 249,995 740,724 The combination of the $ 145,840 43,750 303,573 201,483 5000 201,483 0 100,640 0 The combination of the $ 249,990 75,000 519,742 344,752 104,000 344,752 0 171,878 0 During the year ended October 31, 2024, no no The 2024 Series notes have been extended to March 31, 2025, with required payments in January, February and March of 2025.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Oct. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8– STOCKHOLDERS’ EQUITY Preferred Stock The Company has authorized 5,000,000 0.001 250,000 0 0 Activity for the year ended October 31, 2024 and 2023 There were no sales or grants of preferred shares during the years ended October 31, 2024 and 2023. Common Stock On June 23, 2023, the Board of Directors of the Company approved the Reverse Stock Split of the Company’s (a) authorized shares of Common Stock; and (b) issued and outstanding shares of Common Stock, which became effective on July 6, 2023. As of October 31, 2024, the Company had authorized 19,230,770 0.001 4,460,535 4,430,535 On November 16, 2023, the Company granted 30,000 15.00 450,000 There were no grants of common stock during the year ended October 31, 2023. Stock-Based Compensation There were no The table below presents option activity for the years ended October 31, 2024 and 2023: SCHEDULE OF OPTION ACTiVITY Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (in years) Aggregate intrinsic value Balance at October 31, 2022 1,124,076 $ 10.79 7.64 $ 19,873,680 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited (11,153 ) (6.05 ) ( 7.78 ) - Balance at October 31, 2023 1,112,923 10.84 6.64 16,899,060 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited - - - - Balance at October 31, 2024 1,112,923 $ 10.84 5.64 $ 1,560,431 Stock based compensation expense related to options for the years ended October 31, 2024 and 2023 amounted to $ 1,513,677 1,292,270 934,397 831,333 1,985,988 3,506,561 Warrants During the year ended October 31, 2024, the Company issued pre-funded warrants to purchase 1,107,500 0.01 During the year ended October 31, 2023 the Company did not issue any warrants. A summary of the Company’s common stock underlying the outstanding warrants as of October 31, 2024 and 2023 is as follows: SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS Underlying Number of Average Weighted Outstanding – October 31, 2022 523,300 $ 19.50 2.32 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (78,846 ) 13.00 - Warrants B – Expired during the period - - - Outstanding at October 31, 2023 444,454 20.56 1.65 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (182,804 ) 13.00 - Warrants B – Expired during the period - - - Outstanding – October 31, 2024 261,650 $ 26.00 1.31

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Oct. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Employment agreements On July 6, 2022, the Company hired Christopher Furman as its new Chief Executive Officer. Mr. Furman will receive an annual base salary of $ 400,000 100 192,307 26.00 38,461 38,461 On December 1, 2021, the Company and John Evans entered into a Consulting Agreement (“Evans Consulting Agreement”). Under the terms of the Evans Consulting Agreement, Mr. Evans is to provide advisory services to the CEO and CFO of the Company. The term of the Evans Consulting Agreement is for four years 200,000 250,000 10 On December 8, 2020, the Company entered into a new employment agreement with Tiana States, Chief Manufacturing Officer (the “States Agreement”). Pursuant to the terms of the States Agreement, the Company agreed to pay Mrs. States a base salary of $ 125,000 200,000 five years 50 On December 1, 2020, the Company entered into a new employment agreement with James Musick, Chief Science Officer (the “Musick Agreement”). Pursuant to the terms of the Musick Agreement, the Company agreed to pay Dr. Musick a base salary of $ 150,000 five years 100 On December 1, 2020, the Company entered into a new employment agreement with Dr. Jack Zamora, Chief Executive Officer and President (“Zamora Agreement”) with a term of five years On October 1, 2021, the Company appointed Nathan Haas as the Chief Financial Officer and entered into an employment agreement with him. Pursuant to the terms the Nathan Haas CFO Agreement, the Company agreed to pay Mr. Haas a base salary of $ 175,000 five years 100 On August 1, 2021, the Company entered into a new employment agreement (the “Tanner Haas Agreement”) with Tanner Haas, the chief executive officer of Fitore at the time. The Company agreed to pay Mr. Haas a base salary of $ 135,000 five years 100

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Oct. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS Settlement Agreement with Dr. Zamora As part of the Settlement Agreement dated November 20, 2022 (the “Effective Date”), the parties agreed to confidentiality and non-disparagement restrictions, as well as a release of any potential claims against each other. In addition, certain provisions of Dr. Zamora’s Employment Agreement that survive termination of employment were modified to provide that Dr. Zamora shall not, for a period of one year from the Effective Date, “directly or indirectly solicit any person who has been a customer or employee of the Company during the period of one (1) year prior to the Effective Date.” The Settlement Agreement also provides for the termination of all previous supply agreements between the Company and Dr. Zamora, effective immediately, with such previous agreements to be replaced by the Supply Agreement described below. Standstill Agreement On the Effective Date, in connection with the Settlement Agreement, the Company entered into a Standstill Agreement with Dr. Zamora (the “Standstill Agreement”). Supply Agreement On the Effective Date, in connection with the Settlement Agreement, the Company entered into a Supply Agreement with Dr. Zamora (the “Supply Agreement”), pursuant to which the Company agreed to provide InfiniVive MD Exosome Serum and InfiniVive Daily Serum (the “Cosmetic Products”) to Dr. Zamora at his request. The provision of the Cosmetic Products under the Supply Agreement is subject to minimum and maximum quantity limitations. The Supply Agreement is effective for a period of five years, unless earlier terminated. The Company or Dr. Zamora may terminate the Supply Agreement immediately in prescribed circumstances, including if either party defaults with respect to its obligations under the Supply Agreement and, if the default is capable of being cured, does not cure such default within 30 days after receiving notice of such default. If the Supply Agreement is deemed terminated by Dr. Zamora for failure of the Company to supply the Cosmetic Products in accordance with its terms or by the Company without cause, the Standstill Agreement would be deemed terminated and of no further force or effect. Memorandum of Understanding On the Effective Date, in connection with the Settlement Agreement, the Company entered into a Memorandum of Understanding with Dr. Zamora (the “MOU”) in order to support clinical research for the Company’s AlloRx® stem cells (“AlloRx”). Under the MOU, the Company agreed to provide AlloRx at a specified price to international clinical research facilities or other clinics with which Dr. Zamora may become affiliated, provided that certain regulatory conditions are satisfied, including proof of satisfaction of applicable United States and local legal requirements. The MOU will be effective for a period of five years, unless earlier terminated or replaced by mutual written agreement between Dr. Zamora and the Company. The MOU may also be earlier terminated in the event any clinic or the Company materially breaches the terms and conditions of the MOU. In the event the MOU is terminated by Dr. Zamora for failure of the Company to supply AlloRx in accordance with its terms or by the Company without cause, the Standstill Agreement would be deemed terminated and of no further force or effect. Accounts Receivable and Revenues Dr. Zamora was also a significant customer of the Company in his capacity as a practicing physician. (See Note 9 for more information regarding Dr. Zamora.) As of October 31, 2024 and 2023, Dr. Zamora owed the Company $ 0 0 33,750 36,000 2 2 Accounts Payable and Other Accrued Liabilities The spouse of the Company’s Chief Science Officer, through an entity she controls, leases office and lab space to the Company. As of October 31, 2024 and 2023, the Company owes this entity $ 0 28,222 5,645 Convertible Notes, Debt Discount and Accrued Interest On August 1, 2021, in connection with the acquisition of Fitore (Note 4), the Company issued 2021 Series Unsecured Convertible Notes in the amount of $ 1,000,000 5 July 31, 2024 26.00 200,000 320,000 12,741 480,000 480,000 27,875 23,821 81,679 53,804 225,000 25,000 50,000 Lease with Spouse of Chief Science Officer The spouse of our Chief Science Officer, through entities she controls, leases office and lab space to our company. The rent is $ 5,645 Consulting Agreement with 5% Stockholder On December 1, 2021, we entered into a consulting agreement with John Evans (the “Consulting Agreement”), a greater than 5% stockholder and our former Chief Financial Officer, pursuant to which Mr. Evans provides advisory services to our Chief Executive and Chief Financial Officers. Under the Consulting Agreement, Mr. Evans is paid $200,000 per year for his services, increasing to $250,000 per year upon the Company receiving a financing of $10 million or more. The Consulting Agreement further provides that all prior options granted to Mr. Evans under his prior agreements with the Company, specifically those that were granted on May 1, 2018, November 30, 2020, October 1, 2021, shall survive and continue to vest according to their original terms. The Consulting Agreement will terminate on December 1, 2025 (the “Agreement Termination Date”). If Mr. Evans is terminated by the Company for any reason prior to the Agreement Termination Date, or there occurs a Change in Control (as defined in the Consulting Agreement), Mr. Evans will be entitled to the continued payment of amounts due under the Consulting Agreement for the remaining term of the Consulting Agreement, as well as continued vesting of all outstanding options granted to Mr. Evans.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Oct. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under the provisions of ASC 740, a deferred tax asset or liability (net of a valuation allowance) is provided in the financial statements by applying the provisions of applicable laws to measure the deferred tax consequences of temporary differences that will result in taxable or deductible amounts in future years as a result of events recognized in the financial statements in the current or ensuing years. The Company has not recorded an income tax expense. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company’s ability to realize these assets. Significant components of the Company’s net deferred tax assets for federal and state income taxes at October 31, 2024 and 2023 consist of the following: SCHEDULE OF NET DEFERRED TAX ASSETS FOR FEDERAL AND STATE INCOME TAXES Years Ended October 31, 2024 2023 Net operating loss carryforward $ 4,562,000 $ 3,074,000 Unrecognized holding gains (728,000 ) - Accretion of Debt Discounts 973,000 - Stock compensation 1,952,000 1,579,000 Basis of shares in subsidiary 439,000 442,000 Capitalized intangible costs 127,000 (116,000 ) Accruals and reserves 112,000 69,000 Deferred tax assets 7,437,000 5,048,000 Valuation allowance (7,437,000 ) (5,048,000 ) Effective income tax asset $ – $ – As of October 31, 2024 and 2023, the Company has net operating loss carry forwards of approximately $ 18,069,000 12,102,000 The net operating loss carry forwards generated from tax years ending after December 31, 2017 will not expire. Net operating loss carry forwards generated from tax years ending before January 1, 2018 expire after 20 years. 2,389,000 The valuation allowance is evaluated at the end of each year, considering positive and negative evidence about whether the asset will be realized. At that time, the allowance will either be increased or reduced; reduction could result in the complete elimination of the allowance if positive evidence indicates that the value of the deferred tax asset is no longer impaired, and the allowance is no longer required.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Oct. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 SUBSEQUENT EVENTS On January 21, 2025, a new investor advanced $ 750,000 750,000

NATURE OF ORGANIZATION AND SU_2

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation On June 23, 2023, the Board of Directors of the Company approved a 1-for-26 reverse stock split 0.001 The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, Fitore, Inc. (“Fitore”) and InfiniVive MD, LLC (“InfiniVive”).
Cash Equivalents	Cash Equivalents For the purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Concentrations During the years ended October 31, 2024 and 2023, 2 % and 2 % respectively, of the Company’s total revenues were derived from sales to an entity controlled by the Company’s former Chief Executive Officer and President, Dr. Jack Zamora (“Dr. Zamora”) (Note 10). Dr. Zamora is also a 30 % stockholder. During the year ended October 31, 2024, 33 % and 31 % of the Company’s total revenue was attributable to product sales to two customers. Also, during the year ended October 31, 2023, two customers accounted for 43 % and 15 % of the Company’s revenues. Other than the revenues derived through sales the customers referenced herein, no customer accounted for greater than 10 % of the Company’s gross sales for the years ended October 31, 2024 or 2023. In addition to the product revenue concentrations noted above, the Company recognized $ 25,000 in consulting revenue from a single client during the year ended October 31, 2023. This amount was 1 % of the total revenue recognized for the period.
Deferred Offering Costs	Deferred Offering Costs The Company defers, as Current Assets, the direct incremental costs of raising capital through equity offerings, until such time as the offering is completed or abandoned. At the time of the offering completion, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. During the years ended October 31, 2024 and 2023 the Company recorded as expense $ 2,656,962 0
Financial Instruments	Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements. For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time. Control is considered transferred over time if any one of the following criteria is met: ● The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs; ● The entity’s performance creates or enhances an asset; or ● The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date. For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue. The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below: Sale of research and development product Sales of research and development product include the sale of stem cell medium Sale of therapeutic product: Includes cell culture media to be used in therapeutic treatment. Shipping: Includes amounts charged to customers for shipping products. Consulting Revenue: The Company has agreed to assist another party to develop an FDA-approved biological product. Revenues are recognized when certain contractual milestones are achieved. Fitore product sales online: Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. InfiniVive product sales: InfiniVive, via call-in orders, sells exosomes and daily cosmetic serum Disaggregation of revenue The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Year Ended Year Ended Revenues: Research and development products $ 426,846 $ 574,293 AlloRx Stem Cells to Foreign Third-Party Clinics 1,285,117 893,474 Consulting revenue - 25,000 InfiniVive products 128,940 204,414 Fitore products 14,741 66,270 Total $ 1,855,644 $ 1,763,451 Total Revenues $ 1,855,644 $ 1,763,451
Deferred Revenue	Deferred Revenue The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) executed between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been to be renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement. The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of October 31, 2023, the Company has net deferred $ 525,387 685,005 159,618 The table below summarizes Deferred Revenues as of October 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, 2023 Other Project Income Recognized Net Revenue Deferred October 31, 2024 Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of October 31, 2023: October 31, 2022 Other Project Income Recognized Net October 31, 2023 Deferred Revenue $ 650,000 $ (191,746 ) $ 67,133 $ 525,387 Total $ 650,000 $ (191,746 ) $ 67,133 $ 525,387 As of July 31, 2023, upon the expiration of the European Wellness Agreement, the Company recognized $ 250,000 58,254
Accounts Receivable	Accounts Receivable Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the allowance method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of October 31, 2024 and 2023, total accounts receivable amounted to $ 206,292 119,671 975 975 As of October 31, 2024, three customers accounted for 55 20 10 39 35 10
Basic Loss Per Share	Basic Loss Per Share The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the years ended October 31, 2024 and 2023, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE October 31, 2024 October 31, 2023 Stock options outstanding 1,112,923 1,112,923 Shares to be issued in connection with exercise of warrants 261,650 444,454 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settlement 30,915 13,102 2023 Series Convertible Notes Payable – Stock Settled - warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable - Stock Settled 98,051 41,487 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured Convertible Notes Payable – Stock Settled 857,955 - 2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable 289,583 - 2024 Pre-funded Warrants 1,107,500 - Total 3,827,688 1,681,077 Anti-dilutive shares 3,827,688 1,681,077
Inventory	Inventory Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES October 31, 2024 October 31, 2023 Raw materials $ - $ 18,856 Finished goods 115,365 151,896 Total inventory $ 115,365 $ 170,752 The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the years ended October 31, 2024 and 2023, the Company did not record any impairment expense.
Patents	Patents Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of October 31, 2024 and 2023 were $ 89,548 82,325
Leases	Leases In May 2023, the Company executed a new office lease for its executive offices, with the lease starting July 1, 2023. The Company recognized an initial operating lease right-of-use asset of $ 271,396 271,396 130,150 72,536
Property and Equipment	Property and Equipment Property, equipment, and leasehold improvements are recorded at historical cost. The cost of property and equipment is depreciated over the estimated useful lives, when placed in service (ranging from 3 5
Intangible Assets and Impairment	Intangible Assets and Impairment Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. The Company periodically reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less that the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Goodwill	Goodwill Goodwill is the excess of acquisition cost over the fair value of the net assets of acquired businesses. The Company does not amortize goodwill but assesses goodwill for impairment at least annually or when there has been a material change in circumstances, using the market approach.
Stock Based Compensation	Stock Based Compensation The Company accounts for expenses associated with shares issued for services using the fair value method following the guidance outlined in Section 718-10 of the FASB ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee and non-employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions). That cost is recognized over the period during which the service is provided. No compensation cost is recognized for equity instruments for which service is not provided or rendered.
Recent Accounting Standards	Recent Accounting Standards On August 5, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. This ASU is effective for fiscal years beginning after December 31, 2023. The Company is evaluating the impact the adoption will have on the financial statements.

NATURE OF ORGANIZATION AND SU_3

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF DISAGGREGATION OF REVENUE	The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Year Ended Year Ended Revenues: Research and development products $ 426,846 $ 574,293 AlloRx Stem Cells to Foreign Third-Party Clinics 1,285,117 893,474 Consulting revenue - 25,000 InfiniVive products 128,940 204,414 Fitore products 14,741 66,270 Total $ 1,855,644 $ 1,763,451 Total Revenues $ 1,855,644 $ 1,763,451
SUMMARY OF DEFERRED REVENUES	The table below summarizes Deferred Revenues as of October 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, 2023 Other Project Income Recognized Net Revenue Deferred October 31, 2024 Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of October 31, 2023: October 31, 2022 Other Project Income Recognized Net October 31, 2023 Deferred Revenue $ 650,000 $ (191,746 ) $ 67,133 $ 525,387 Total $ 650,000 $ (191,746 ) $ 67,133 $ 525,387
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE October 31, 2024 October 31, 2023 Stock options outstanding 1,112,923 1,112,923 Shares to be issued in connection with exercise of warrants 261,650 444,454 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settlement 30,915 13,102 2023 Series Convertible Notes Payable – Stock Settled - warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable - Stock Settled 98,051 41,487 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured Convertible Notes Payable – Stock Settled 857,955 - 2024 Series Senior Secured Convertible Notes Payable – Stock Settled – warrants issuable 289,583 - 2024 Pre-funded Warrants 1,107,500 - Total 3,827,688 1,681,077 Anti-dilutive shares 3,827,688 1,681,077
SCHEDULE OF INVENTORIES	Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES October 31, 2024 October 31, 2023 Raw materials $ - $ 18,856 Finished goods 115,365 151,896 Total inventory $ 115,365 $ 170,752

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Oct. 31, 2024
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES	As of October 31, 2024 and 2023, the estimated fair values of the Company’s financial liabilities are presented in the following table: SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES October 31, 2024 2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability $ 9,024 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 116,982 2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 154,966 Total $ 280,972 October 31, 2023 2023 Series Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability $ 63,969 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 829,294 Total $ 893,263
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS	The following table presents a roll-forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2024 Series Senior Secured Convertible Notes Payable and its 2023 Series Convertible Notes Payable, categorized as Level 3: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS Year Ended Year Ended October 31, 2023 Beginning Balance $ 893,263 $ - Additions 3,159,788 996,598 Subtractions (990,719 ) - Total (gains) or losses (realized/unrealized) (2,781,360 ) (103,335 ) Ending Balance $ 280,972 $ 893,263
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED	The fair value of the warrants granted in connection with the two tranches of 2023 Series Convertible Notes Payable-Stock Settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED October 31, 2024 October 31, 2023 Risk-free interest rate - % 3.60 3.93 % Dividend yield - % 0.00 % Volatility factor - % 161.52 200.29 % Weighted average expected life (years) - 2.5
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED	The fair value of the warrants granted in connection with the 2024 Series Senior Secured convertible notes payable - stock settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED October 31, 2024 October 31, 2023 Risk-free interest rate 3.99 4.61 % - % Dividend yield 0.00 % - % Volatility factor 131.93 135.58 % - % Weighted average expected life (years) 2.5 -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Oct. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates: SCHEDULE OF PROPERTY AND EQUIPMENT October 31, 2024 October 31, 2023 Leasehold improvements $ 12,840 $ 12,840 Property and equipment 1,046,925 1,046,925 Total cost 1,059,765 1,059,765 Less accumulated depreciation (920,213 ) (739,351 ) Net property and equipment $ 139,552 $ 320,414

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Oct. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL	The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2024: SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL Remaining Cost Accumulated Amortization and Impairment Net Carrying Trademarks and tradenames 11.75 $ 693,330 $ (534,654 ) $ 158,676 Patents, know-how and unpatented technology 11.75 710,060 (510,652 ) 199,408 Customer relationships 0 114,536 (114,536 ) - Total 1,517,926 (1,159,842 ) 358,084 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (1,351,459 ) $ 3,171,581 The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2023: Remaining Cost Accumulated Amortization and Impairment Net Carrying Trademarks and tradenames 12.75 $ 693,330 $ (391,214 ) $ 302,116 Patents, know-how and unpatented technology 12.75 710,060 (356,648 ) 353,412 Customer relationships 0.75 114,536 (102,251 ) 12,285 Total 1,517,926 (850,113 ) 667,813 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (914,091 ) $ 3,608,949
SCHEDULE OF FUTURE AMORTIZATION EXPENSE	The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31; SCHEDULE OF FUTURE AMORTIZATION EXPENSE 2025 $ 30,475 2026 30,475 2027 30,475 2028 30,475 2029 30,475 Total $ 152,375

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Oct. 31, 2024
Lease Obligations
SCHEDULE OF BALANCE SHEET RELATED TO LEASES	The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets: SCHEDULE OF BALANCE SHEET RELATED TO LEASES Leases Balance Sheet Location October 31, 2024 October 31, 2023 Assets Noncurrent: Operating Right-of-use asset – operating lease $ 346,091 $ 476,241 Finance Property and equipment, net 3,351 33,294 Total Lease Assets $ 349,442 $ 509,535 Liabilities Current: Operating Operating lease liabilities $ 119,486 $ 130,150 Finance Finance lease liabilities 12,081 61,832 Noncurrent: Operating Operating lease liabilities 226,605 346,091 Finance Finance lease liabilities 5,042 17,123 Total Lease Liabilities $ 363,214 $ 555,196
SCHEDULE OF OPERATIONS RELATED TO LEASES	The following table shows the classification and location and the Company’s lease costs in the Consolidated Statements of Operations: SCHEDULE OF OPERATIONS RELATED TO LEASES Location 2024 2023 Statements of Operations Years Ended October 31, Location 2024 2023 Operating lease expense General and administrative expense $ 203,557 $ 203,274 Finance lease expense: Interest on lease liability Interest expense 7,992 9,795 Total Lease expense $ 211,549 $ 213,069
SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES	Minimum contractual obligations for the Company’s leases (undiscounted) as of October 31, 2024 were as follows: SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES Operating Finance Fiscal year 2025 $ 163,902 $ 12,803 Fiscal year 2026 166,760 5,150 Fiscal year 2027 84,609 - Fiscal year 2028 67,734 - Fiscal year 2029 67,734 - Thereafter 45,156 - Total Lease Payments $ 595,895 $ 17,953 Less Imputed interest (249,804 ) (830 ) Total lease liability $ 346,091 $ 17,123
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES	The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated: SCHEDULE OF OTHER INFORMATION RELATED TO LEASES October 31, 2024 October 31, 2023 Operating Leases Finance Leases Operating Leases Finance Leases Weighted-average remaining lease term (in years) 4.0 1.34 4.9 1.41 Weighted-average discount rate (1) 10.00 % 6.67 % 10.00 % 7.49 % (1) The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES	The following table includes other quantitative information for the Company’s leases for the periods indicated: SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES 2024 2022 Years Ended October 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities Cash payments for operating leases $ 180,581 $ 133,598 Cash payments for finance leases $ 65,387 $ 71,566

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Oct. 31, 2024
Debt Disclosure [Abstract]
SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS	The table below presents outstanding debt instruments as of October 31, 2024 and October 31, 2023: SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS October 31, 2024 October 31, 2023 Short Term 2021 Series convertible notes – related party $ 480,000 $ 480,000 2024 Senior secured convertible notes payable 4,718,750 - Total Short-Term Debt 5,198,750 480,000 Long Term Unsecured 6% note payable – related party $ 767,288 $ 767,288 Unsecured 4% note payable – related party 1,221,958 1,221,958 2022 Series convertible notes 200,000 200,000 2023 Series convertible notes – stock settled 405,000 405,000 Discount 2023 Series convertible notes (51,886 ) (64,285 ) 2023 Series B convertible notes – stock settled 1,312,600 1,312,600 Discount 2023 Series B convertible notes (805,327 ) (891,582 ) Total Long-Term Debt 3,049,633 2,950,979 Total Debt $ 8,248,383 $ 3,430,979
SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS	The table below presents the future maturities of outstanding debt obligations as of October 31, 2024: SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS Fiscal year 2025 $ 5,198,750 Fiscal year 2026 1,989,246 Fiscal year 2027 200,000 Fiscal year 2028 1,717,600 Total $ 9,105,596

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Oct. 31, 2024
Equity [Abstract]
SCHEDULE OF OPTION ACTiVITY	The table below presents option activity for the years ended October 31, 2024 and 2023: SCHEDULE OF OPTION ACTiVITY Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (in years) Aggregate intrinsic value Balance at October 31, 2022 1,124,076 $ 10.79 7.64 $ 19,873,680 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited (11,153 ) (6.05 ) ( 7.78 ) - Balance at October 31, 2023 1,112,923 10.84 6.64 16,899,060 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited - - - - Balance at October 31, 2024 1,112,923 $ 10.84 5.64 $ 1,560,431
SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS	A summary of the Company’s common stock underlying the outstanding warrants as of October 31, 2024 and 2023 is as follows: SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS Underlying Number of Average Weighted Outstanding – October 31, 2022 523,300 $ 19.50 2.32 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (78,846 ) 13.00 - Warrants B – Expired during the period - - - Outstanding at October 31, 2023 444,454 20.56 1.65 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (182,804 ) 13.00 - Warrants B – Expired during the period - - - Outstanding – October 31, 2024 261,650 $ 26.00 1.31

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2024
Income Tax Disclosure [Abstract]
SCHEDULE OF NET DEFERRED TAX ASSETS FOR FEDERAL AND STATE INCOME TAXES	Significant components of the Company’s net deferred tax assets for federal and state income taxes at October 31, 2024 and 2023 consist of the following: SCHEDULE OF NET DEFERRED TAX ASSETS FOR FEDERAL AND STATE INCOME TAXES Years Ended October 31, 2024 2023 Net operating loss carryforward $ 4,562,000 $ 3,074,000 Unrecognized holding gains (728,000 ) - Accretion of Debt Discounts 973,000 - Stock compensation 1,952,000 1,579,000 Basis of shares in subsidiary 439,000 442,000 Capitalized intangible costs 127,000 (116,000 ) Accruals and reserves 112,000 69,000 Deferred tax assets 7,437,000 5,048,000 Valuation allowance (7,437,000 ) (5,048,000 ) Effective income tax asset $ – $ –

SCHEDULE OF DISAGGREGATION OF R

SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 1,855,644	$ 1,763,451
Research and Development Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	426,846	574,293
AlloRx Stem Cells to Foreign Third Party Clinics [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	1,285,117	893,474
Consulting Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues		25,000
InfiniVive Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	128,940	204,414
Fitore Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 14,741	$ 66,270

SUMMARY OF DEFERRED REVENUES (D

SUMMARY OF DEFERRED REVENUES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Regulatory Liability [Line Items]
Deferred Revenue Beginning	$ 525,387	$ 650,000
Other Project Income Recognized		(191,746)
Revenue Deferred		67,133
Deferred Revenue Ending	525,387	525,387
Deferred Revenue [Member]
Regulatory Liability [Line Items]
Deferred Revenue Beginning	525,387	650,000
Other Project Income Recognized		(191,746)
Revenue Deferred		67,133
Deferred Revenue Ending	$ 525,387	$ 525,387

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	3,827,688	1,681,077
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	1,112,923	1,112,923
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	261,650	444,454
2021 Series Convertible Notes Payable - Related Party - Common Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	18,462	18,462
2022 Series Convertible Notes Payable - Common Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	7,692	7,692
2023 Series Convertible Notes Payable – Stock Settlement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	30,915	13,102
2023 Series Convertible Notes Payable – Stock Settled – Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	3,076	3,076
2023 Series B Convertible Notes Payable – Stock Settled [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	98,051	41,487
2023 Series B Convertible Notes Payable - Stock Settled - Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	39,881	39,881
2024 Series Senior Secured Convertible Notes Payable – Stock Settled [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	857,955
2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	289,583
2024 Prefunded Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	1,107,500

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials		$ 18,856
Finished goods	115,365	151,896
Total inventory	$ 115,365	$ 170,752

NATURE OF ORGANIZATION AND SU_4

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 23, 2023	Jan. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	May 31, 2023
Product Information [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-26 reverse stock split	1 to 26 reverse stock split
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Revenue from Contract with Customer, Excluding Assessed Tax			$ 1,855,644	$ 1,763,451
Deferred offering costs			2,656,962	0
Deferred revenue current			525,387	525,387
Composed of deferred revenue				685,005
Prepaid project cost				159,618
Accounts receivables, related parties			206,292	119,671
Allowance for doubtful accounts receivable			975	975
Capitalized patent costs			89,548	82,325
Operating lease right of use asset			346,091	476,241		$ 271,396
Operating lease liability			346,091			$ 271,396
Amortization of operating lease - right-of-use asset			$ 130,150	72,536
Minimum [Member]
Product Information [Line Items]
Property and equipment, estimated useful lives			3 years
Maximum [Member]
Product Information [Line Items]
Property and equipment, estimated useful lives			5 years
European Wellness Agreement [Member]
Product Information [Line Items]
Deferred revenue current					$ 250,000
Project related expenses					$ 58,254
Consulting Revenue [Member]
Product Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 25,000
[custom:TotalRevenuePercentage]				1%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			43%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			15%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]
Product Information [Line Items]
Concentration risk percentage			10%	10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Zamora [Member]
Product Information [Line Items]
Concentration risk percentage			2%	2%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Dr Jack Zamora [Member]
Product Information [Line Items]
Concentration risk percentage			30%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			33%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			31%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			55%	39%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			20%	35%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | No Customer [Member]
Product Information [Line Items]
Concentration risk percentage			10%	10%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage			10%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 9,873,560	$ 5,356,717
Working capital deficit	$ 9,100,000

SCHEDULE OF FAIR VALUE ON FINAN

SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	$ 280,972	$ 893,263
2023 Series Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	9,024	63,969
2023 Series B Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	116,982	$ 829,294
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	$ 154,966

SCHEDULE OF FAIR VALUE DERIVATI

SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS (Details) - Derivative [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance	$ 893,263
Additions	3,159,788	996,598
Subtractions	(990,719)
Total (gains) or losses (realized/unrealized)	(2,781,360)	(103,335)
Ending Balance	$ 280,972	$ 893,263

SCHEDULE OF FAIR VALUE DERIVA_2

SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED (Details)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		3.60
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		3.93
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.99
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.61
Measurement Input, Expected Dividend Payment [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		0
Measurement Input, Expected Dividend Payment [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		161.52
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		200.29
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	131.93
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	135.58
Measurement Input, Expected Term [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, weighted average expected life		2 years 6 months
Measurement Input, Expected Term [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, weighted average expected life	2 years 6 months

FAIR VALUE MEASUREMENT (Details

FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized (gain) loss derivative warrant liability	$ 2,781,360	$ 103,335
2023 Series Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized (gain) loss derivative warrant liability	767,257	$ 103,335
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized gain on derivatives	$ 2,014,103

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 12,840	$ 12,840
Property and equipment	1,046,925	1,046,925
Total cost	1,059,765	1,059,765
Less accumulated depreciation	(920,213)	(739,351)
Net property and equipment	$ 139,552	$ 320,414

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 180,862	$ 153,023

SCHEDULE OF INTANGIBLE ASSETS A

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,517,926	$ 1,517,926
Accumulated Amortization	(1,159,842)	(850,113)
Net Carrying Value	358,084	667,813
Net Carrying Value	$ 3,171,581	$ 3,608,949
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	Indefinite	Indefinite
Cost	$ 4,523,040	$ 4,523,040
Impairment	(1,351,459)	(914,091)
Net Carrying Value	$ 3,171,581	$ 3,608,949
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	11 years 9 months	12 years 9 months
Cost	$ 693,330	$ 693,330
Accumulated Amortization	(534,654)	(391,214)
Net Carrying Value	$ 158,676	$ 302,116
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	11 years 9 months	12 years 9 months
Cost	$ 710,060	$ 710,060
Accumulated Amortization	(510,652)	(356,648)
Net Carrying Value	$ 199,408	$ 353,412
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	0 years	9 months
Cost	$ 114,536	$ 114,536
Accumulated Amortization	(114,536)	(102,251)
Net Carrying Value		$ 12,285

SCHEDULE OF FUTURE AMORTIZATION

SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)	Oct. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 30,475
2026	30,475
2027	30,475
2028	30,475
2029	30,475
Total	$ 152,375

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Amortization of intangible assets	$ 63,702	$ 131,736
Impairment expense	683,394	577,852
Fitore Inc [Member]
Impairment expense	49,431	243,795
Goodwill and impairment expense	437,368
Infini Vive MD [Member]
Impairment expense	$ 196,595	$ 334,057

SCHEDULE OF BALANCE SHEET RELAT

SCHEDULE OF BALANCE SHEET RELATED TO LEASES (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023	May 31, 2023
Lease Obligations
Operating	$ 346,091	$ 476,241	$ 271,396
Finance	$ 3,351	$ 33,294
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and Equipment, Net	Property and Equipment, Net
Total Lease Assets	$ 349,442	$ 509,535
Operating	119,486	130,150
Finance	12,081	61,832
Operating	226,605	346,091
Finance	5,042	17,123
Total Lease Liabilities	$ 363,214	$ 555,196

SCHEDULE OF OPERATIONS RELATED

SCHEDULE OF OPERATIONS RELATED TO LEASES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Lease Obligations
Operating lease expense	$ 203,557	$ 203,274
Interest on lease liability	7,992	9,795
Total Lease expense	$ 211,549	$ 213,069

SCHEDULE OF MINIMUM CONTRACTUAL

SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES (Details) - USD ($)	Oct. 31, 2024	May 31, 2023
Lease Obligations
Operating lease, 2025	$ 163,902
Finance lease 2025	12,803
Operating lease, 2026	166,760
Finance lease, 2026	5,150
Operating lease, 2027	84,609
Finance lease, 2027
Operating lease, 2028	67,734
Finance lease, 2028
Operating lease, 2029	67,734
Operating lease, 2029
Operating lease, thereafter	45,156
Finance lease, thereafter
Operating lease, total lease payments	595,895
Finance lease, total lease payments	17,953
Operating lease, less imputed interest	(249,804)
Finance lease, less imputed interest	(830)
Operating lease, total lease liability	346,091	$ 271,396
Finance lease, total lease liability	$ 17,123

SCHEDULE OF OTHER INFORMATION R

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)		Oct. 31, 2024	Oct. 31, 2023
Lease Obligations
Weighted-average remaining lease term, operating leases		4 years	4 years 10 months 24 days
Weighted-average remaining lease term, finance leases		1 year 4 months 2 days	1 year 4 months 28 days
Weighted-average discount rate, operating lease	[1]	10%	10%
Weighted-average discount rate, finance leases	[1]	6.67%	7.49%
[1]The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.

SCHEDULE OF CASH FLOW INFORMATI

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Lease Obligations
Cash payments for operating leases	$ 180,581	$ 133,598
Cash payments for finance leases	$ 65,387	$ 71,566

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative)	12 Months Ended
	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)	May 31, 2023 USD ($) ft²
Lease Obligations
Lessee operating lease renewal term	5 years
Area of land | ft²			2,978
Operating lease right of use asset	$ 346,091	$ 476,241	$ 271,396
Operating lease liability	346,091		$ 271,396
Amortization expense	$ 130,150	$ 72,536

SCHEDULE OF OUTSTANDING DEBT IN

SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Debt Disclosure [Abstract]
2021 Series convertible notes – related party	$ 480,000	$ 480,000
2024 Senior secured convertible notes payable	4,718,750
Total Short-Term Debt	5,198,750	480,000
Long Term
Unsecured 6% note payable – related party	767,288	767,288
Unsecured 4% note payable – related party	1,221,958	1,221,958
2022 Series convertible notes	200,000	200,000
2023 Series convertible notes – stock settled	405,000	405,000
Discount 2023 Series convertible notes	(51,886)	(64,285)
2023 Series B convertible notes – stock settled	1,312,600	1,312,600
Discount 2023 Series B convertible notes	(805,327)	(891,582)
Total Long-Term Debt	3,049,633	2,950,979
Total Debt	$ 8,248,383	$ 3,430,979

SCHEDULE OF FUTURE MATURITIES O

SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS (Details)	Oct. 31, 2024 USD ($)
Debt Disclosure [Abstract]
Fiscal year 2025	$ 5,198,750
Fiscal year 2026	1,989,246
Fiscal year 2027	200,000
Fiscal year 2028	1,717,600
Total	$ 9,105,596

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)								1 Months Ended							12 Months Ended
	Jul. 16, 2024	May 13, 2024	Apr. 11, 2024	Jan. 10, 2024	Nov. 16, 2023	Jun. 23, 2023	Jan. 06, 2023	Jul. 31, 2023	Jun. 30, 2023	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Jul. 31, 2022	Jun. 30, 2022	Oct. 31, 2024	Oct. 31, 2023	Apr. 30, 2025	Mar. 31, 2025	Feb. 28, 2025	Jan. 31, 2025	Jan. 10, 2025	Jan. 08, 2025	Jul. 01, 2024	Jun. 21, 2024	Apr. 30, 2024
Debt Instrument [Line Items]
Shares issued, price per share															$ 0.75
Pre-money valuation amount															$ 200,000,000
Conversion price												$ 0.25
Conversion price trigger												0.75			$ 0.75
Exercise price of warrants												$ 16.25			$ 16.25
Reverse stock split, description						1-for-26 reverse stock split						1 to 26 reverse stock split
Warrants and Rights Outstanding, Term															5 years
Debt percent															200%
Inception of the stock settled debt									$ 175,000		$ 262,533	$ 135,000
Warrant liability															$ 126,006	$ 893,263
Accretion expense															$ 3,952,197	$ 40,730
Share price																							$ 5.50
Number of shares, exercised
Minimum [Member]
Debt Instrument [Line Items]
Share price																							5
Maximum [Member]
Debt Instrument [Line Items]
Share price																							6
January 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest															$ 58,729	$ 26,240
Beneficial conversion feature															135,000
Debt discount															208,213
Debt net discount															$ 73,213
Effective interest rate															13%	13%
Accretion expense															$ 12,400	$ 8,927
Fair value adjustment of warrants															54,946	9,243
Interest expense, debt															32,489	26,240
March 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest															100,495	$ 37,314
Beneficial conversion feature															262,533
Debt discount															831,108
Debt net discount															$ 568,574
Effective interest rate															44.60%	44.60%
Accretion expense															$ 52,724	$ 22,176
Fair value adjustment of warrants															427,408	70,973
Interest expense, debt															63,181	37,314
June 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest															57,666	$ 15,551
Beneficial conversion feature															175,000
Debt discount															529,810
Debt net discount															$ 354,810
Effective interest rate															39.50%	39.50%
Accretion expense															$ 33,532	$ 9,627
Fair value adjustment of warrants															284,903	23,119
Interest expense, debt															42,115	15,551
2024 Series Senior Secured Convertible [Member]
Debt Instrument [Line Items]
Accrued interest															0	0
Purchase price		$ 300,000	$ 175,000	$ 1,000,000	$ 2,000,000
Interest expense, debt															$ 0
Principal amount		$ 375,000	$ 218,750	$ 1,250,000	$ 2,500,000																			$ 3,750,000
Discount rate		20%	20%	20%	20%
Share price															$ 15
2024 January Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature															$ 249,995
Debt discount															5,232,309
Debt net discount															3,482,304
Effective interest rate				624%	659%
Accretion expense															3,482,304	0
Fair value adjustment of warrants															1,713,320
Original issuance discount															750,000
Debt issuance discount															75,000
Beneficial conversion feature															2,500,005
Additional extinguishment of gross proceeds															300,000
Extinguishment of original warrant liability															990,719
Gain on transition															740,724
2024 April Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature															145,840
Debt discount															303,573
Debt net discount															$ 201,483
Effective interest rate															5,000%
Accretion expense															$ 201,483	0
Fair value adjustment of warrants															100,640	0
Debt issuance discount															43,750
2024 May Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature															249,990
Debt discount															519,742
Debt net discount															$ 344,752
Effective interest rate															104,000%
Accretion expense															$ 344,752	0
Fair value adjustment of warrants															171,878	0
Debt issuance discount															$ 75,000
January 2023 Notes and January 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature												135,000
Warrant liability												73,213
Debt discount												208,213
March 2023 Notes and March 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature											262,533
Warrant liability											568,574
Debt discount											831,108
June 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature									175,000
Warrant liability									354,180
Debt discount									529,810
2024 January Senior Secured Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Stock issued upon conversion															416,667
Stock issued upon conversion, value															$ 2,500,005
2024 April Senior Secured Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Stock issued upon conversion															24,306
Stock issued upon conversion, value															$ 145,840
2024 May Senior Secured Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Stock issued upon conversion															41,666
Stock issued upon conversion, value															$ 249,990
2024 July Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Share price																							$ 5.50
2024 July Senior Secured Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Stock issued upon conversion															1,250,000
Stock issued upon conversion, value															$ 249,995
January 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability value												$ 73,213
March 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability											568,574
June 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability									354,810
Series 2024 Warrants [Member] | 2024 Series Senior Secured Convertible [Member]
Debt Instrument [Line Items]
Exercise price of warrants																									$ 15
Debt conversion, description															The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale.
Warrant exercisable and liquidity event description															The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis.
Series 2024 Warrants [Member] | 2024 January Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature															$ 2,500,005
Warrant liability															2,732,304
Debt discount															$ 5,232,309
Number of shares, exercised															250,000
Series 2024 Warrants [Member] | 2024 April Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Warrant liability value															$ 157,733
Beneficial conversion feature															145,840
Warrant liability															157,733
Debt discount															$ 303,573
Number of shares, exercised															14,583
Debt issuance discount															$ 43,750
Series 2024 Warrants [Member] | 2024 May Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Warrant liability value															269,752
Beneficial conversion feature															249,990
Warrant liability															269,752
Debt discount															$ 519,742
Number of shares, exercised															25,000
Debt issuance discount															$ 75,000
Purchase Agreement [Member]
Debt Instrument [Line Items]
Purchase price															5,000,000
Target Consolidation Agreement [Member]
Debt Instrument [Line Items]
Additional paid	$ 300,000
Subscription amount	3,300,000
Original issue discount	825,000
Original principal amount	$ 4,125,000
Unsecured 6% Note Payable Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense															46,163	46,037
Accrued interest															184,275	138,112
Unsecured 4% Note Payable Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense															49,012	48,879
Accrued interest															195,648	146,635
2021 Series Convertible Note - Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense															27,875	23,821
Convertible notes payable															$ 480,000	480,000
Debt instrument, maturity date															Jul. 31, 2024
Accrued interest															$ 81,679	53,804
2021 Series Convertible Note - Related Party Debt [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Convertible notes payable																						$ 225,000
Non bearing interest																	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 25,000
2022 Series Convertible Notes [Member]
Debt Instrument [Line Items]
Interest expense															10,028	10,000
Accrued interest															$ 23,233	$ 13,205
Convertible notes payable													$ 5,000,000	$ 5,000,000
Purchase price													$ 200,000	$ 200,000
Debt instrument, convertible, threshold percentage of stock price trigger													5%	5%
2023 Series Convertible Notes Stock Settled [Member]
Debt Instrument [Line Items]
Purchase price							$ 405,000	$ 525,000	$ 525,000	$ 787,600	$ 787,600
Debt instrument, convertible, threshold percentage of stock price trigger							8%	8%	8%	8%	8%

SCHEDULE OF OPTION ACTiVITY (De

SCHEDULE OF OPTION ACTiVITY (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Equity [Abstract]
Number of Shares, Balance	1,112,923	1,124,076
Weighted Average Exercise Price per Share, Balance	$ 10.84	$ 10.79
Weighted Average Remaining Contractual Life (in years)	5 years 7 months 20 days	6 years 7 months 20 days	7 years 7 months 20 days
Aggregate intrinsic value, Balance	$ 16,899,060	$ 19,873,680
Number of Shares, Exercised
Weighted Average Exercise Price per Share, Exercised
Number of Shares, Granted
Weighted Average Exercise Price per Share, Granted
Number of Shares, Expired
Weighted Average Exercise Price per Share, Expired
Number of Shares, Forfeited		(11,153)
Weighted Average Exercise Price per Share, Forfeited		$ (6.05)
Weighted Average Remaining Contractual Life, forfeited		7 years 9 months 10 days
Number of Shares, Balance	1,112,923	1,112,923	1,124,076
Weighted Average Exercise Price per Share, Balance	$ 10.84	$ 10.84	$ 10.79
Aggregate intrinsic value, Balance	$ 1,560,431	$ 16,899,060	$ 19,873,680

SCHEDULE OF COMMON STOCK UNDERL

SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details) - $ / shares	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Class of Warrant or Right [Line Items]
Underlying number of shares beginning	444,454	523,300
Average exercise price beginning	$ 20.56	$ 19.50
Weighted average life ending	1 year 3 months 21 days	1 year 7 months 24 days	2 years 3 months 25 days
Underlying number of shares ending	261,650	444,454	523,300
Average exercise price ending	$ 26	$ 20.56	$ 19.50
Warrants A [Member]
Class of Warrant or Right [Line Items]
Underlying number of shares granted
Average exercise price, granted
Underlying number of shares expirations	(182,804)	(78,846)
Average exercise price, expired	$ 13	$ 13
Warrants B [Member]
Class of Warrant or Right [Line Items]
Underlying number of shares granted
Average exercise price, granted
Underlying number of shares expirations
Average exercise price, expired

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)		12 Months Ended
	Nov. 16, 2023	Oct. 31, 2024	Oct. 31, 2023	Jun. 23, 2023	Jan. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized		5,000,000	5,000,000
Preferred stock, par value		$ 0.001	$ 0.001
Common stock, shares authorized		19,230,770	19,230,770
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued		4,460,535	4,430,535
Common stock, shares outstanding		4,460,535	4,430,535
Shares granted, price per share		$ 0.75
Number of shares granted		0	0
Stock based compensation expense		$ 1,513,677	$ 1,292,270
Share based compensation options, exercisable		934,397	831,333
Unrecognized compensation expense		$ 1,985,988	$ 3,506,561
Warrants exercise price per share		$ 16.25			$ 16.25
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		1,107,500
Warrants exercise price per share		$ 0.01
Common Stock [Member]
Class of Stock [Line Items]
Shares granted		30,000
Common Stock [Member] | Consulting Agreement [Member]
Class of Stock [Line Items]
Shares granted	30,000
Shares granted, price per share	$ 15
Consulting expense		$ 450,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		250,000	250,000
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)							12 Months Ended
	Jul. 06, 2022	Dec. 01, 2021	Oct. 01, 2021	Aug. 01, 2021	Dec. 08, 2020	Dec. 01, 2020	Oct. 31, 2024	Oct. 31, 2023
Common stock purchase options exercise price
Christopher Furman [Member] | Employment Agreements [Member]
Base salary	$ 400,000
Annual bonus percentage	100%
Common stock purchase options	192,307
Common stock purchase options exercise price	$ 26
Share based compensation, options vested	38,461
John Evans [Member] | Consulting Agreement [Member]
Agreement term		4 years
Officers compensation		$ 200,000
Salaries wages and officers compensation increased		250,000
Proceeds from estimated financing related party		$ 10,000,000
Tiana States [Member] | New Employment Agreements [Member]
Base salary					$ 125,000
Annual bonus percentage					50%
Agreement term					5 years
Salaries wages and officers compensation increased					$ 200,000
James Musick [Member] | Musick Agreement [Member]
Base salary						$ 150,000
Annual bonus percentage						100%
Agreement term						5 years
Jack Zamora [Member] | Zamora Agreement [Member]
Agreement term						5 years
Nathan Haas [Member] | CFO Agreement [Member]
Base salary			$ 175,000
Annual bonus percentage			100%
Agreement term			5 years
Tanner Haas [Member] | Tanner Haas Agreement [Member]
Base salary				$ 135,000
Annual bonus percentage				100%
Agreement term				5 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)

12 Months Ended

Apr. 15, 2022

Dec. 01, 2021

Oct. 22, 2021

Aug. 01, 2021

Oct. 31, 2024

Oct. 31, 2023

Apr. 30, 2025

Mar. 31, 2025

Feb. 28, 2025

Jan. 31, 2025

Jan. 10, 2025

Jan. 08, 2025

Jan. 31, 2023

Oct. 31, 2022

Related Party Transaction [Line Items]

Product sales revenue

$ 1,855,644

$ 1,763,451

Rent

0

28,222

Rent per month

5,645

Debt instrument convertible conversion price

$ 0.25

Consulting Agreement [Member]

Related Party Transaction [Line Items]

Consulting agreement description

Mr. Evans is paid $200,000 per year for his services, increasing to $250,000 per year upon the Company receiving a financing of $10 million or more. The Consulting Agreement further provides that all prior options granted to Mr. Evans under his prior agreements with the Company, specifically those that were granted on May 1, 2018, November 30, 2020, October 1, 2021, shall survive and continue to vest according to their original terms.

2021 Series Unsecured Convertible Notes [Member]

Related Party Transaction [Line Items]

Unsecured convertible debt

$ 1,000,000

Interest rate

5%

Debt instrument maturity date

Jul. 31, 2024

Debt instrument convertible conversion price

$ 26

Debt conversion amount

$ 320,000

$ 200,000

Convertible notes payable

480,000

$ 480,000

Interest expense

27,875

23,821

Accrued interest

$ 81,679

53,804

2021 Series Unsecured Convertible Notes [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Shares issued in conversion

12,741

2021 Series Convertible Note - Related Party Debt [Member]

Related Party Transaction [Line Items]

Debt instrument maturity date

Jul. 31, 2024

Convertible notes payable

$ 480,000

480,000

Interest expense

27,875

23,821

2021 Series Convertible Note - Related Party Debt [Member] | Subsequent Event [Member]

Related Party Transaction [Line Items]

Convertible notes payable

$ 225,000

Non bearing interest

$ 50,000

$ 50,000

$ 50,000

$ 50,000

$ 25,000

Jack Zamora [Member]

Related Party Transaction [Line Items]

Due from related parties, current

0

0

Product sales revenue

$ 33,750

$ 36,000

Product sales percentage

2%

2%

SCHEDULE OF NET DEFERRED TAX AS

SCHEDULE OF NET DEFERRED TAX ASSETS FOR FEDERAL AND STATE INCOME TAXES (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 4,562,000	$ 3,074,000
Unrecognized holding gains	(728,000)
Accretion of Debt Discounts	973,000
Stock compensation	1,952,000	1,579,000
Basis of shares in subsidiary	439,000	442,000
Capitalized intangible costs	127,000	(116,000)
Accruals and reserves	112,000	69,000
Deferred tax assets	7,437,000	5,048,000
Valuation allowance	(7,437,000)	(5,048,000)
Effective income tax asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Operating loss carry forward	$ 18,069,000	$ 12,102,000
Operating loss expiration description	The net operating loss carry forwards generated from tax years ending after December 31, 2017 will not expire. Net operating loss carry forwards generated from tax years ending before January 1, 2018 expire after 20 years.
Valuation allowances	$ 2,389,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	Jan. 21, 2025 USD ($)
2025 Senior Secured Note [Member]
Subsequent Event [Line Items]
Advance paid to investors	$ 750,000
2024 Senior Secured Convertible Note [Member]
Subsequent Event [Line Items]
Advance paid to investors	$ 750,000